Bendamustine/Polatuzumab-vedotin/RituximabLack of efficacy

被引:0
|
作者
机构
关键词
D O I
10.1007/s40278-024-59369-0
中图分类号
学科分类号
摘要
引用
收藏
页码:113 / 113
相关论文
共 50 条
  • [25] Disseminated tuberculosis after Polatuzumab-Vedotin based chemoimmunotherapy in a patient with Burkitt's lymphoma
    Elkourashy, Sarah A.
    Benkhadra, Maria
    Shafei, Laila
    Abujarir, Sulieman
    Ghasoub, Rola
    CLINICAL CASE REPORTS, 2024, 12 (05):
  • [26] Efficacy of retreatment with polatuzumab vedotin in combination with rituximab in polatuzumab vedotin-resistant DLBCL models
    Kawasaki, Natsumi
    Tomita, Mayu
    Yamashita-Kashima, Yoriko
    Yoshimura, Yasushi
    Yoshiura, Shigeki
    LEUKEMIA & LYMPHOMA, 2023, 64 (12) : 1938 - 1948
  • [27] Refractory hemophagocytic lymphohistiocytosis secondary to polatuzumab vedotin plus rituximab and bendamustine
    Kebing Lv
    Fancong Kong
    Min Yu
    Yulan Zhou
    Fei Li
    Annals of Hematology, 2024, 103 : 1017 - 1019
  • [28] Refractory hemophagocytic lymphohistiocytosis secondary to polatuzumab vedotin plus rituximab and bendamustine
    Lv, Kebing
    Kong, Fancong
    Yu, Min
    Zhou, Yulan
    Li, Fei
    ANNALS OF HEMATOLOGY, 2024, 103 (03) : 1017 - 1019
  • [29] Molecular Determinants of Sensitivity to Polatuzumab-Vedotin in Diffuse Large B-Cell Lymphoma
    Corcoran, Sean R.
    Choi, Jaewoo
    Fenner, Rachel E.
    Yu, Xin
    Scheich, Sebastian
    Hsiao, Tony
    Schevchenko, Galina
    Morris, Vivian M.
    Phelan, James D.
    Papachristou, Evangelia K.
    Kishore, Kamal
    D'Santos, Clive S.
    Ji, Yanlong
    Pittaluga, Stefania
    Wright, George
    Urlaub, Henning
    Pan, Kuan-Ting
    Oellerich, Thomas
    Muppidi, Jagan R.
    Hodson, Daniel James
    Staudt, Louis M.
    BLOOD, 2023, 142